PT  - JOURNAL ARTICLE
AU  - Livia O Loureiro
AU  - Jennifer L Howe
AU  - Miriam Reuter
AU  - Alana Iaboni
AU  - Kristina Calli
AU  - Delnaz Roshandel
AU  - Iva Pritisanac
AU  - Alan Moses
AU  - Julie D. Forman-Kay
AU  - Brett Trost
AU  - Mehdi Zarrei
AU  - Olivia Rennie
AU  - Lynette Lau
AU  - Christian R Marshall
AU  - Siddharth Srivastava
AU  - Brianna Godlewski
AU  - Elizabeth Buttermore
AU  - Mustafa Sahin
AU  - Dean Hartley
AU  - Thomas Frazier
AU  - Jacob Vorstman
AU  - Stelios Georgiades
AU  - Suzanne ME Lewis
AU  - Peter Szatmari
AU  - Lisa Bradley
AU  - Richard Delorme
AU  - Thomas Bourgeron
AU  - Evdokia Anagnostou
AU  - Stephen W. Scherer
TI  - A recurrent <em>SHANK3</em> frameshift variant in Autism Spectrum Disorder
AID  - 10.1101/2021.05.01.21256144
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.01.21256144
4099  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256144.short
4100  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256144.full
AB  - Autism Spectrum Disorder (ASD) is genetically complex, but specific copy number variants (CNVs; e.g., 1q21.1, 16p11.2) and genes (e.g., NRXN1, NLGN4) have been identified as penetrant susceptibility factors, and all of these demonstrate pleiotropy. Many ASD-associated CNVs are, in fact, genomic disorder loci where flanking segmental duplications lead to recurrent deletion and duplication events of the same region in unrelated individuals, but these lesions are large and involve multiple genes. To identify opportunities to establish a more specific genotype and phenotype correlation in ASD, we searched genomic data, and the literature, for recurrent predicted damaging sequence-level variants affecting single genes. We identified 17 individuals from 15 unrelated families carrying a heterozygous guanine duplication (rs797044936; NM_033517.1; c.3679dup; p.Ala1227Glyfs*69) occurring within a string of 8 guanines (at genomic location [hg38]g.50,721,512dup) affecting SHANK3, a prototypical ASD gene (6/7,521 or 0.08% of ASD-affected individuals studied by whole genome sequencing carried the p.Ala1227Glyfs*69 variant). This variant, which is predicted to cause a frameshift leading to a premature stop codon truncating the C-terminal region of the corresponding protein, was not reproducibly found in any of the control groups we analyzed. All probands identified carried de novo mutations with the exception of five individuals in three families who inherited it through somatic mosaicism. This same heterozygous variant in published mouse models leads to an ASD-like phenotype. We scrutinized the phenotype of p.Ala1227Glyfs*69 carriers, and while everyone (16/16) formally tested for ASD carried a diagnosis, there was variable expression of core ASD features both within families and between families, underscoring the impact of as yet unknown modifiable factors affecting expressivity in autism.Competing Interest StatementS.W.S. is on the Scientific Advisory Committees of Deep Genomics, Population Bio and an Academic Consultant for the King Abdulaziz University.Funding StatementThis work was funded by Autism Speaks, Autism Speaks Canada, the University of Toronto McLaughlin Centre, the Canada Foundation for Innovation, the Canadian Institutes of Health Research (CIHR), Genome Canada/Ontario Genomics Institute, the Government of Ontario, Brain Canada, Ontario Brain Institute Province of Ontario Neurodevelopmental Disorders (POND), and The Hospital for Sick Children Foundation. L.O.L holds Lap-Chee Tsui Postdoctoral Fellowship from The Hospital for Sick Children. S.W.S holds the Endowed Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SickKids Research Ethics BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the MSSNG and SSC data can be obtained by completing data access agreements (https://research.mss.ng and https://www.sfari.org/resource/sfari-base, respectively), as was done for this study. These two well-established and stable whole genome sequence and phenotype resources are utilized by approved investigators worldwide. The 1000G genome-sequencing data are publicly available via Amazon Web Services (https://docs.opendata.aws/1000genomes/readme.html). Access to other data through other publications or resources is described in the main text. https://research.mss.ng/ https://www.sfari.org/resource/simons-simplex-collection/